炎症性肠病合并贫血的研究进展

Advances in the inflammatory bowel disease associated anemia

贫血是炎症性肠病(IBD)患者常见的并发症之一,会导致生活质量下降,也可增加患者的住院频率。据报道IBD并发贫血的发病率为6～74[1]。IBD患者贫血的发病机制尚未完全明了,铁摄入与丢失的负平衡、慢性病所致贫血、VitB12和叶酸缺乏、药物介导、炎症因子、溶血等众多因素均可能参与贫血的发生。过去普遍认为贫血是IBD不可避免的伴随症状,往往重视度不够,但最近的观点强调,贫血是此类患者明确的治疗内容。

Anemia is a frequent and serious complication in patients with inflammatory bowel disease （IBD）, with reported prevalence varying from 6 % to 74 %. Anemia is associated with a decrease in the quality of life and increased rate of hospitalization. The pathogenesis of IBD-associated anemia remains unknown and represents an example of combined iron deficiency anemia （IDA） and anemia of chronic diseases （ACD）. Cobalamin or folate deficiency, drug induced anemia, inflammatory factors and other causes of anemia such as hemolysis are seen less frequently. In the past, it was common to ascribe anemia as an unavoidable accompaniment of IBD, but recently, correction of anemia is being emphasized as a specific therapeutic objective in these patients.